SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (1488)3/3/2000 8:47:00 AM
From: nigel batesRead Replies (2) of 4974
 
This really boggles -

March 3, 2000--PE Corp. today announced the exercise by its underwriters of an over-allotment option to purchase 570,000 shares of Celera Genomics common stock associated with its follow-on stock offering announced March 1, 2000.
Including the over-allotment, the public offering totaled 4,370,000 shares at $225.00 per share, with net proceeds expected to be approximately $944 million.

The appetite for stock clearly NOT satiated.

Note MEDX raising funds today too.

nig
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News